Cipla vs Divi's Laboratories Q3 FY26

Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY). PAT of INR 676 crore included a one-time INR 276 crore labor code charge. U.S. revenue fell to $167 million as Lenalidomide tapered and lanreotide supply was disrupted (partner Pharmathen paused production after FDA observations; resupply expected H1 FY27). India business grew 10% YoY, with respiratory crossing INR 5,000 crore. FY26 EBITDA margin guidance revised to ~21%. Key upcoming U.S. launches (4 respiratory, 4 peptide assets) are expected to offset revenue declines, but near-term headwinds persist. Risk: lanreotide disruption may extend beyond H1 FY27 if remediation is delayed.

Guidance read

FY26 EBITDA margin guidance revised to ~21%: Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact. U.S. launches: 4 respiratory and 4 peptide assets in FY27: Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza. Lanreotide resupply expected in H1 FY27: Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway. FY27 guidance to be provided next quarter: Management will provide FY27 guidance after finalizing the annual operating plan.

Risk read

Key risks include Lanreotide supply disruption may extend beyond H1 FY27 — Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.; U.S. launch pipeline may face delays or competition — Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.; Elevated R&D spend may persist, pressuring margins — R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.; Semaglutide generic launch could impact tirzepatide uptake — Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Divis Laboratories reported Q3 FY26 consolidated total income of INR 2,692 crore, up 12% YoY, driven by strong custom synthesis (57% mix) and stable generics volume. PAT stood at INR 583 crore, flat YoY due to a one-time exceptional item of INR 74 crore from labour code changes. Gross margins improved sharply to 63.7% (material consumption 36.3% of sales vs 39.8% last year) on favourable product mix. Management highlighted three dedicated CS projects progressing towards commercialization by Q3-Q4 CY2027, with validations ongoing. Peptide capabilities advanced with a dedicated commercial building for SPPS. Nutraceuticals contributed INR 214 crore in the quarter. Risks include continued generic pricing pressure and potential input cost impact from China's export tax rebate withdrawal. Overall, the company is well-positioned for double-digit growth with a strong pipeline and capacity expansion.

Guidance read

Three dedicated CS projects to commercialize by Q3-Q4 CY2027: Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027. Double-digit revenue growth trajectory maintained: Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases. Phase two expansion at Kakinada under evaluation: Company is evaluating a second phase expansion at Unit 3 with 4 additional production blocks, but no final decision or timeline announced.

Risk read

Key risks include Generic pricing pressure persists — Pricing environment for generics remains competitive, limiting value growth despite volume increases.; China export tax rebate withdrawal may increase input costs — China's removal of export tax rebates on certain chemicals could lead to selective pricing pressures on raw materials, though company has diversified 78% of procurement domestically.; Regulatory approval delays for CS projects — Commercialization of three dedicated CS projects depends on customer regulatory approvals, which could face delays beyond the guided Q3-Q4 CY2027 timeline.; Concentration risk in peptide segment — Peptide capacity is largely dedicated to a single customer's requirements, creating dependency; management declined to disclose details on diversification..

Promise ledger

Of 2 tracked promises, management 0 met, 0 close, 2 missed.